E-selectin antagonists for hematopoietic cell mobilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for mobilizing peripheral blood stem cells, such as those used in autologous hematopoietic stem cell transplantation, are not universally effective, with high failure rates in patients with lymphomas, multiple myeloma, and acute leukemia, and existing agents like G-CSF and AMD3100 have limitations in terms of toxicity and cost.
Innovation Solution
Development of E-selectin antagonists, specifically glycomimetic compounds and antibodies, peptides, or aptamers that inhibit E-selectin interaction, facilitating the mobilization of hematopoietic stem cells and tumor cells from the bone marrow by competing with sLe(x) or sLe(a) binding sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If G-CSF is used for mobilization of peripheral blood stem cells, then stem cell mobilization is achieved, but high failure rates occur in patients with lymphomas, multiple myeloma, and acute leukemia
Solution Approach 1:
The patent segments the mobilization process by using different agents for different patient populations. G-CSF is used for general cases while E-selectin antagonists are specifically applied for patients with lymphomas, multiple myeloma, and acute leukemia who have high failure rates with G-CSF alone, creating a segmented treatment approach that addresses the versatility problem
Solution Approach 2:
The patent employs composite treatment strategies by combining E-selectin antagonists with G-CSF in certain patient populations, creating a composite therapeutic approach that leverages the strengths of both agents to improve overall mobilization success rates across diverse patient groups
2Reliability
If existing agents like G-CSF and AMD3100 are used for stem cell mobilization, then mobilization efficacy is achieved, but toxicity and cost limitations arise
Solution Approach 1:
The patent changes the chemical structure parameters by developing E-selectin antagonist compounds with specific molecular characteristics (formula I with defined R1-R8 substituents) that achieve effective E-selectin inhibition while maintaining favorable toxicity profiles, representing a parameter change from existing agents
Solution Approach 2:
The patent describes compounds that can be administered as single-dose or limited-dose regimens for stem cell mobilization, reducing the need for prolonged treatment and associated cumulative toxicity, aligning with the concept of using shorter-acting, cost-effective therapeutic interventions
3Reliability
If existing agents like G-CSF and AMD3100 are used for stem cell mobilization, then mobilization efficacy is achieved, but high cost is incurred
Solution Approach 1:
The patent describes E-selectin antagonist compounds that can be synthesized with potentially lower manufacturing costs compared to biologics like G-CSF and AMD3100, and can be administered as single-dose regimens, reducing overall treatment cost while maintaining mobilization efficacy
Solution Approach 2:
The patent changes the therapeutic parameter by using small molecule E-selectin antagonists (formula I compounds) instead of protein-based agents, representing a shift from high-cost biologics to potentially more cost-effective small molecule therapeutics with similar or superior efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The E-selectin antagonists effectively mobilize hematopoietic and tumor cells from the bone marrow, offering a potentially less toxic and more cost-effective alternative to existing methods, improving the success rate of stem cell mobilization and therapeutic outcomes.
Implementation Method 1
E-selectin antagonists, specifically glycomimetic compounds and antibodies, peptides, or aptamers that inhibit E-selectin interaction, facilitating the mobilization of hematopoietic stem cells and tumor cells from the bone marrow by competing with sLe(x) or sLe(a) binding sites
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Methods are provided herein for use of E-selectin antagonists for mobilizing cells, such as hematopoietic cells, hematopoietic stem cells and progenitor cells, white blood cells, and malignant cells, and hematopoietic tumor cells from the bone marrow. More specifically, methods are provided for using E-se!ectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers, and peptides for mobilizing cells from the bone marrow to the peripheral vasculature and tissues.